+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension)

Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension)

Journal of the American College of Cardiology 62(12): 1092-1100

This study was designed to test the safety and efficacy of pulmonary artery (PA) denervation (PADN) for patients with idiopathic PA hypertension (IPAH) not responding optimally to medical therapy. Baroreceptors and sympathetic nerve fibers are localized in or near the bifurcation area of the main PA. We previously demonstrated that PADN completely abolished the experimentally elevated PA pressure responses to occlusion of the left interlobar PA. Of a total of 21 patients with IPAH, 13 patients received the PADN procedure, and the other 8 patients who refused the PADN procedure were assigned to the control group. PADN was performed at the bifurcation of the main PA, and at the ostial right and left PA. Serial echocardiography, right heart catheterization, and a 6-min walk test (6MWT) were performed. The primary endpoints were the change of PA pressure (PAP), tricuspid excursion (Tei) index, and 6MWT at 3 months follow-up. Compared with the control group, at 3 months follow-up, the patients who underwent the PADN procedure showed significant reduction of mean PAP (from 55 ± 5 mm Hg to 36 ± 5 mm Hg, p < 0.01), and significant improvement of the 6MWT (from 324 ± 21 m to 491 ± 38 m, p < 0.006) and of the Tei index (from 0.7 ± 0.04 to 0.50 ± 0.04, p < 0.001). We report for the first time the effect of PADN on functional capacity and hemodynamics in patients with IPAH not responding optimally to medical therapy. Further randomized study is required to confirm the efficacy of PADN. (First-in-Man Pulmonary Artery Denervation for Treatment of Pulmonary Artery Hypertension [PADN-1] study; chiCTR-ONC-12002085).

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 055287098

Download citation: RISBibTeXText

PMID: 23850902

DOI: 10.1016/j.jacc.2013.05.075

Related references

Pulmonary artery denervation to treat pulmonary arterial hypertension a single-center, prospective, first-in-man PADN-1 study. Journal of the American College of Cardiology, 2013

Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study. Circulation. Cardiovascular Interventions 8(11): E002837, 2016

Pulmonary Artery Denervation Significantly Increases 6-Min Walk Distance for Patients With Combined Pre- and Post-Capillary Pulmonary Hypertension Associated With Left Heart Failure: The PADN-5 Study. Jacc. Cardiovascular Interventions 12(3): 274-284, 2019

Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension. Circulation. Cardiovascular Interventions 8(11): E002569, 2016

Pulmonary arterial hypertension: pharmacologic therapies and potential pulmonary artery denervation treatment. Eurointervention 9 Suppl R: R149-R154, 2014

Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline. Jacc. Cardiovascular Interventions 8(15): 2013-2023, 2016

Pulmonary Artery Denervation by Determining Targeted Ablation Sites for Treatment of Pulmonary Arterial Hypertension. Circulation. Cardiovascular Interventions 10(10), 2017

Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo. Eurointervention 9(2): 269-276, 2014

Pericardial effusion is correlated with clinical outcome after pulmonary artery denervation for pulmonary arterial hypertension. Oncotarget 8(33): 54106-54114, 2017

Transthoracic Pulmonary Artery Denervation for Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology 2019: Atvbaha118311992, 2019

Pulmonary artery denervation for treatment of a patient with pulmonary hypertension secondary to left heart disease. Pulmonary Circulation 6(2): 240-243, 2016

Pulmonary artery denervation improves pulmonary arterial hypertension induced right ventricular dysfunction by modulating the local renin-angiotensin-aldosterone system. Bmc Cardiovascular Disorders 16(1): 192, 2017

Pulmonary Artery Denervation: A New, Long-Awaited Interventional Treatment for Combined Pre- and Post-Capillary Pulmonary Hypertension?. Jacc. Cardiovascular Interventions 12(3): 285-288, 2019

Will Pulmonary Artery Denervation Really Have a Place in the Armamentarium of the Pulmonary Hypertension Specialist?. Jacc. Cardiovascular Interventions 12(8): 799-800, 2019

Pulmonary Artery Catheterization Complicated By Pulmonary Artery Rupture In A Woman With Severe Pulmonary Arterial Hypertension: Can She Survive?. Chest 134(4): c47001-a-c47001-b, 2008